BOSTON, MA. — September 22, 2021 — Scorpion Therapeutics was selected today as one of this year’s Endpoints 11, a group of the most promising up-and-coming private biotechnology companies.
“Scorpion Therapeutics is honored to be among the prestigious 2021 Endpoints 11 companies,” said Dr. Axel Hoos, CEO. “The discovery of novel medicines has always required innovation and conviction, and it is incredibly validating to be recognized alongside like-minded companies who share our goal of addressing therapeutic white spaces in patient care.”
Scorpion Therapeutics’ unique Precision Oncology 2.0 platform integrates 20 years of scientific and technological innovation, thus accelerating drug discovery and enhancing the selectivity of our compounds against targets to achieve the highest impact on cancer while sparing normal tissues. The Company is on a trajectory of growth with strong momentum in progressing lead precision oncology programs for multiple cancer indications.
About Scorpion Therapeutics
Scorpion Therapeutics is a next-generation oncology company developing best-in-class or first-in-class precision medicines to deliver transformational outcomes for patients. To achieve this, Scorpion is applying world-leading expertise in medicinal and computational chemistry paired with chemical proteomics and latest advances in target biology to improve tumor targeting and access to previously undruggable targets for many cancer patients.
Media Contact:
Ravi Moorthy
Scorpion Therapeutics
ravi@scorpiontx.com
Media Contact:
Hannah Deresiewicz
Stern Investor Relations, Inc.
hannah.deresiewicz@sternir.com